# A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

> **NCT04934670** · PHASE3 · TERMINATED · sponsor: **Xenikos** · enrollment: 12 (actual)

## Conditions studied

- Steroid-Refractory Acute Graft Versus Host Disease

## Interventions

- **DRUG:** T-Guard
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04934670
- **Lead sponsor:** Xenikos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-16
- **Primary completion:** 2022-11-10
- **Final completion:** 2023-01-19
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms
- **Last updated:** 2024-08-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04934670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04934670, "A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04934670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*